Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Dabigatran Etexilate Mesylate in Healthy Chinese Subjects
NCT06876623Phase 1Completed
- Sponsor
- Affiliated Hospital of Guizhou Medical University
- Start
- Dec 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dabigatran etexilate oral solution in Atrial fibrillation (AFib) (4 arms), sponsored by Affiliated Hospital of Guizhou Medical University. Primary endpoints: Maximum Observed Serum or Plasma Concentration at 2 days, Area Under the Concentration-Time Curve from 0 to t at 2 days and 1 more. Started Dec 2019; status: completed.
02
Drugs
dabigatran etexilate oral solution
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06876623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06876623.